Psychiatric aspects of Parkinson's disease

Current Opinion in Psychiatry

Volumn 18, Issue 3, 2005, Pages 335-341

  Ehrt, Uwe ^a   Aarsland, Dag ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cognitive impairment; Dementia; Depression; Parkinson's disease; Psychotic symptoms

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BRAIN DEPTH STIMULATION; COGNITION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; FRONTAL LOBE; HALLUCINATION; HIGH RISK POPULATION; HUMAN; NAUSEA; NEUROPSYCHIATRY; PARIETAL LOBE; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SUBTHALAMIC NUCLEUS; TEMPORAL LOBE;

EID: 17844408701     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000165605.21424.03     Document Type: Review

References (70)

1. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2:229-237.
2. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19:1043-1049. Eighty-six elderly non-demented Parkinson's disease patients and 102 control subjects were followed for 4 years and assessed with the CMACOG battery. Thirty-five percent of Parkinson's disease and 7% of the control subjects had dementia at follow-up. The relative risk of dementia in Parkinson's disease versus controls was 5.1 (95% CI 2.1-12.5).
3. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56:730-736.
4. Louis ED, Tang MX, Mayeux R. Parkinsonian signs in older people in a community-based study: risk of incident dementia. Arch Neurol 2004; 61:1273-1276. In a prospective study of 1028 elderly subjects without dementia or Parkinson's disease, those with mild parkinsonian signs had a 57% higher risk of dementia than those without such signs.
5. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61:1906-1911. One hundred and twenty-nine Parkinson's disease patients were assessed with the MMSE 4 and 8 years after baseline. The annual rate of decline was 1.1 (95% CI 0.8-1.3), compared with 0.1 in a healthy control group. Parkinson's disease patients with dementia had an annual decline of 2.3 (2.1-2.5), comparable to the decline of 2.6 (2.3-2.8) in Alzheimer patients.
6. Dujardin K, Defebvre L, Duhamel A, et al. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 2004; 251:1383-1392. This was the first prospective study of cognition and cortical single photon emission computed tomography in subjects with recently diagnosed Parkinson's disease. Cognitive impairment after 3 years was predicted by tests of executive impairment and delayed recall as well as reduced perfusion of temporo-parieto-occipital cortices.
7. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3:19-28.
8. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17:137-145.
9. Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004; 63:2091-2096. The authors performed a detailed study of different aspects of visual perception in Parkinson's disease with and without dementia, DLB and Alzheimer's disease and healthy controls (total 116). Profound impairment of visual perception was found in DLB and PDD. Interestingly, in PDD, visual impaiment was most pronounced in those with hallucinations.
10. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CJT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61:919-925.
11. Walker Z, Costa DC, Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004; 62:1568-1572. The results from this study and that by O'Brien et al. [10] showed abnormal striatal dopamine transporter in DLB and PDD, and suggest that single photon emission computed tomography can be used to distinguish between patients with DLB/ PDD and Alzheimer's disease.
12. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127:791-800. This was the first study of magnetic resonance imaging findings in Parkinson's disease with (n = 26) and without (n = 31) dementia using voxel-based morphometry. PDD patients showed widespread cortical atrophy, whereas non-demented Parkinson's disease patients had frontal lobe atrophy. A similar pattern of atrophy was found in PDD and DLB.
13. Gwinn-Hardy K. Genetics of parkinsonism. Mov Disord 2002; 17:645-656.
14. Singleton A, Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose? Lancet 2004; 364:1105-1107.
15. Levy G, Louis ED, Mejia-Santana H, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 2004; 61:1033-1039. The authors studied the familial aggregation of Parkinson's disease and Alzheimer's disease in two large cohorts of Parkinson's disease and normal control subjects. The risk of Alzheimer's disease was not increased in relatives of patients with Parkinson's disease compared with relatives of controls. The authors conclude that there are not major genetic contributions to the etiology of Parkinson's disease and Alzheimer's disease.
16. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997; 244:2-8.
17. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127:550-560. This is the first study of cognition in a community-based cohort of incident Parkinson's disease. The authors found that 36% of these early Parkinson's disease patients had cognitive impairment, and 8% had marked impairment. Interestingly, within the group with cognitive impairment, they distinguished one subgroup with frontostriatal type deficit, one with temporal type deficit, and one with global impairment.
18. Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003; 15:126-131.
19. Bruck A, Kurki T, Kaasinen V, et al. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004; 75:1467-1469. The authors studied magnetic resonance imaging and cognition in 20 non-medicated subjects with early-stage Parkinson's disease. They found atrophy of the prefrontal cortex which correlated with disturbance on a vigilance task, and of left hiccopcampus, which correlated with verbal memory impairment.
20. Camicioli R, Moore MM, Kinney A, et al. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003; 18:784-790.
21. Johnson AM, Almeida QJ, Slough C, et al. Visual inspection time in Parkinson's disease: deficits in early stages of cognitive processing. Neuropsychologia 2004; 42:577-583.
22. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59:1714-1720.
23. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351:2509-2518. This was the first multicentre, placebo-controlled trial of dementia in Parkinson's disease. Modest, but statistically significant benefit of rivastigmine was found on all primary (Alzheimer's Disease Assessment Scale Cognitive Subscale, Alzheimer's Disease and Clinical Global Impression of Change) and secondary (MMSE, Neuropsychiatric Inventory, an activities of daily living scale, attention, and executive tests) outcome measures.
24. Laatu S, Revonsuo A, Pihko L, et al. Visual object recognition deficits in early Parkinson's disease. Parkinsonism Relat Disord 2004; 10:227-233.
25. Dujardin K, Blairy S, Defebvre L, et al. Deficits in decoding emotional facial expressions in Parkinson's disease. Neuropsychologia 2004; 42:239-250.
26. Henry JD, Crawford JR. Verbal fluency deficits in Parkinson's disease: a meta-analysis. J Int Neuropsychol Soc 2004; 10:608-622.
27. Uekermann J, Daum I, Bielawski M, et al. Differential executive control impairments in early Parkinson's disease. J Neural Transm Suppl 2004; 68:39-51.
28. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995; 28:240-258.
29. Oikawa H, Sasaki M, Ehara S, Abe T. Substantia innominata: MR findings in Parkinson's disease. Neuroradiology 2004; 46:817-821.
30. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000; 16:365-379.
31. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:399-406.
32. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19:1-8.
33. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17:164-171.
34. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004; 61:865-868. In a prospective study 97 patients with Parkinson's disease were evaluated after 3.6 years. Hyperhomocysteinemic patients (n = 31) were more likely to be depressive and perform worse on neuropsychometric tasks than normohomocysteinemic patients (n = 66).
35. Sinforiani E, Banchieri L, Zucchella C, et al. Cognitive rehabilitation in Parkinson's disease. Arch Gerontol Geriatr Suppl 2004; 9:387-391.
36. Burn DJ, Troster AI. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr Psychiatry Neurol 2004; 17:172-180.
37. Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:834-839. A consecutive series of 77 Parkinson's disease patients was assessed before, 1 and 3 years after bilateral STN DBS. Depression improved whereas apathy and thought disorders worsened. There was no global cognitive deterioration. However, some patients developed severe depression, suicidal ideation (one completed suicide), hypomania, aggressive behaviour or psychosis.
38. Woods SP, Fields JA, Troster AI. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review. Neuropsychol Rev 2002; 12:111-126.
39. Morrison CE, Borod JC, Perrine K, et al. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol 2004; 19:165-181. Seventeen Parkinson's disease patients were tested before and after bilateral STN stimulator implantation, on and off stimulation. Relative to changes seen in the controls, treated patients had mild impairment of attention and language functions. STN stimulation, per se, had little effect on cognition.
40. Witt K, Pulkowski U, Herzog J, et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol 2004; 61:697-700.
41. Leentjens AF. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17:120-126.
42. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110:118-123. For 90 Parkinson's disease patients and 50 controls mortality was ascertained at 11 years foliow-up. Psychological variables are important predictors of mortality in Parkinson's disease.
43. Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52:784-788. A cross-sectional study of a convenience sample of 114 Parkinson's disease patients receiving specialty care. Multivariate analysis determined effect of depression and other nonmotor symptoms on disability. Increasing severity of depression and worsening cognition were associated with greater disability using the UPDRS ADL score.
44. Nuti A, Ceravolo R, Piccinni A, et al. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol 2004; 11:315-320.
45. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53:175-179.
46. Lauterbach EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2004; 16:29-36.
47. Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16:315-319.
48. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:1171-1174.
49. Koch G, Oliveri M, Brusa L, et al. High-frequency rTMS improves time perception in Parkinson disease. Neurology 2004; 63:2405-2406.
50. Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004; 75:1260-1264.
51. Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol 2002; 59:807-811.
52. Ready RE, Friedman J, Grace J, Fernandez H. Testosterone deficiency and apathy in Parkinson's disease: a pilot study. J Neurol Neurosurg Psychiatry 2004; 75:1323-1326.
53. Okun MS, DeLong MR, Hanfelt J, et al. Plasma testosterone levels in Alzheimer and Parkinson diseases. Neurology 2004; 62:411-413.
54. Okun MS, Walter BL, McDonald WM, et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol 2002; 59:1750-1753.
55. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003; 60:1756-1761.
56. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63:293-300.
57. Tomer R, Aharon-Peretz J. Novelty seeking and harm avoidance in Parkinson's disease: effects of asymmetric dopamine deficiency. J Neurol Neurosurg Psychiatry 2004; 75:972-975.
58. Merims D, Shabtai H, Korczyn AD, et al. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004; 111:1447-1453. The authors evaluated a big sample of 422 consecutive patients. The mean levodopa dose for hallucinators (n = 90) was not significantly different from that in patients without hallucinations. Supplementary treatment with amantadine, selegiline, dopamine agonists, entacapone and anticholinergics did not increase the risk for the development of hallucinations.
59. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998; 351:1032-1033.
60. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord 2002; 17:221-222.
61. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, et al. Olanzapine can worsen parkinsonism. Neurology 1998; 50:1183-1184.
62. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26:643-659.
63. Goetz C, Koller W, Poewe W, et al. Drugs to treat dementia and psychosis: management of Parkinson's disease. Mov Disord 2002; 17(Suppl 4):S120-S127.
64. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27:153-156. The efficacy and safety of quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis was studied in a randomized, open-label, blinded-rater, parallel 12 weeks group trial. Forty patients, 20 on clozapine and 20 on quetiapine, completed the study. The psychopathologic state improved significantly in both treatment groups. No differences were found between clozapine and quetiapine at any assessment time. Side effects were mild, generally transient, and well tolerated.
65. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17:676-681.
66. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27:4-5.
67. Schonfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson's disease psychosis. Am J Psychiatry 2004; 161:373-374.
68. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75:689-695. This was a 4-week, randomized double blind controlled trial of clozapine and placebo, followed by a 12-week clozapine open period, plus a 1-month wash out period, in 60 patients with Parkinson's disease. The mean positive subscore of PANSS improved by 5.6 for the clozapine group and 0.8 for the placebo group. No significant worsening of motor function was observed. At the end of the open period, 25 patients had completely recovered from delusions and hallucinations. Nineteen experienced a relapse within 1 month after the clozapine washout period.
69. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2004; 19:831-833. Psychiatrically stable Parkinson's disease patients with a history of drug-induced psychosis on quetiapine or clozapine were weaned off their antipsychotic drug. After the antipsychotic agent was discontinued, psychosis recurred in five of six patients. In three patients the 'rebound psychosis' was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses.
70. Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004; 27:90-92.